BioVersys AG Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-21.81	-18.72	-18.3
Depreciation & Amortization	0.3	0.28	0.27
Stock-Based Compensation	0.66	1.86	1.72
Other Adjustments	1.85	0.45	0.93
Changes in Accounts Payable	2.69	-2.8	4.8
Changes in Other Operating Activities	-5.63	3.36	-1.08
Operating Cash Flow	-21.95	-15.57	-11.66
Operating Cash Flow Growth	-	-	-
Capital Expenditures	-0.22	-0.04	-0.05
Purchases of Investments	-	-17	-10.83
Proceeds from Sale of Investments	6	15	14.18
Investing Cash Flow	5.78	-2.04	3.29
Long-Term Debt Issued	6.93	-	7.38
Long-Term Debt Repaid	-4.03	-0.03	-0.03
Net Long-Term Debt Issued (Repaid)	2.9	-0.03	7.35
Issuance of Common Stock	76.84	14.71	0.02
Net Common Stock Issued (Repurchased)	76.84	14.71	0.02
Other Financing Activities	-7.16	4.51	-0.24
Financing Cash Flow	72.58	19.19	7.13
Foreign Exchange Rate Adjustments	-0.53	0.66	-0.95
Net Cash Flow	55.89	2.24	-1.23
Free Cash Flow	-22.16	-15.61	-11.7
Free Cash Flow Growth	-	-	-
FCF Margin	-897.97%	-1287.06%	-1027.57%
Free Cash Flow Per Share	-3.95	-4.68	-3.92
Levered Free Cash Flow	-21.8	-17.95	-7
Unlevered Free Cash Flow	-22.81	-17.92	-13.75